

**Editor**

Josef S Smolen

**Associate Editors**

Francis Berenbaum  
Dimitrios Boumpas  
Mary Crow  
Kimme Hyrich  
Rik Lories  
Iain McInnes  
Caroline Ospelt  
Thomas Pap  
David Pisetsky  
Désirée van der Heijde  
Kazuhiko Yamamoto

**Editorial office**

Annals of the Rheumatic Diseases  
BMJ Publishing Group Ltd  
BMA House  
Tavistock Square  
London WC1H 9JR, UK  
T: +44 (0)20 3655 5889  
E: [ard@bmj.com](mailto:ard@bmj.com)  
Twitter: @ARD\_BMJ  
ISSN: 0003-4967 (print)  
ISSN: 1468-2060 (online)

**Disclaimer:** The Editor of *ARD* has been granted editorial freedom and *ARD* is published in accordance with editorial guidelines issued by the World Association of Medical Editors and the Committee on Publication Ethics. *ARD* is primarily intended for healthcare professionals and its content is for information only. The Journal is published without any guarantee as to its accuracy or completeness and any representations or warranties are expressly excluded to the fullest extent permitted by law. Readers are advised to independently verify any information on which they choose to rely. Acceptance of advertising by *ARD* does not imply endorsement. Neither *EULAR* nor BMJ Publishing Group Limited shall have any liability for any loss, injury or damage howsoever arising from *ARD* (except for liability which cannot be legally excluded).

**Copyright:** © 2022 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced in any form without permission.

*ARD* is published by BMJ Publishing Group Ltd typeset by Exeter Premedia Services Private Ltd, Chennai, India and printed in the UK on acid-free paper.

*Annals of the Rheumatic Diseases*, ISSN 0003-4967 (USPS 2152) is published monthly by BMJ Publishing Group Ltd, BMA House, Tavistock Square, WC1H 9JR London. Airfreight and mailing in the USA by agent named World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Periodicals postage paid at Brooklyn, NY 11256. US Postmaster: Send address changes to *Annals of the Rheumatic Diseases*, World Container Inc, 150-15, 183rd Street, Jamaica, NY 11413, USA. Subscription records are maintained at BMA House, Tavistock Square, WC1H 9JR London. Air Business Ltd is acting as our mailing agent.

**Editorial**

- 1483** Defining the targets in SLE management: insights and unmet gaps  
*M Zen, M Gatto, A Doria*

**Viewpoint**

- 1486** Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography?  
*D Poddubnyy, T Diekhoff, X Baraliakos, K G A Hermann, J Sieper*

**Rheumatoid arthritis**

- 1491** Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial  
*A-R Balanescu, G Citera, V Pascual-Ramos, D L Bhatt, C A Connell, D Gold, A-S Chen, G Sawyerr, A B Shapiro, J E Pope, H Schulze-Koops*
- 1504** Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF- $\alpha$ -mediated ERK1/2 and JAK-STAT1 pathways  
*Y Qin, M-L Cai, H-Z Jin, W Huang, C Zhu, A Bozec, J Huang, Z Chen*

**Spondyloarthritis**

- 1515** Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial  
*D van der Heijde, X Baraliakos, J Sieper, A Deodhar, R D Inman, H Kameda, X Zeng, Y Sui, X Bu, A L Pangan, P Wung, I-H Song*
- 1524** Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data analysis from the European Network of Pregnancy Registries in Rheumatology (EuNeP)  
*Y Meissner, A Strangfeld, A Molto, F Forger, M Wallenius, N Costedoat-Chalumeau, H Bjørngaard, M Couderc, R-M Flipo, G Guettrot-Imbert, I Haase, B Jakobsen, H S S Kokesvik, C Richez, J Sellam, A Weiß, A Zbinden, R Fischer-Betz, EuNeP collaborator group*
- 1534** Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study  
*F Proft, S Lüders, T Hunter, G Luna, V Rios Rodriguez, M Protopopov, K Meier, G Kokolakis, K Ghoreschi, D Poddubnyy*

**Systemic lupus erythematosus**

- 1541** Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort  
*M F Ugarte-Gil, J Hanly, M Urowitz, C Gordon, S-C Bae, J Romero-Diaz, J Sanchez-Guerrero, S Bernatsky, A E Clarke, D J Wallace, D A Isenberg, A Rahman, J T Merrill, P R Fortin, D D Gladman, I N Bruce, M Petri, E M Ginzler, M A Dooley, R Ramsey-Goldman, S Manzi, A Jönsen, R F van Vollenhoven, C Aranow, M Mackay, G Ruiz-Irastorza, S Lim, M Inanc, K Kalunian, S Jacobsen, C Peschken, D L Kamen, A Askanase, B A Pons-Estel, G S Alarcón*
- 1549** Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up  
*Q Fu, C Wu, M Dai, S Wang, J Xu, L Dai, Z Li, L He, X Zhu, L Sun, L Lu, C Bao*
- 1556** Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus  
*R F van Vollenhoven, K C Kalunian, T Dörner, B H Hahn, Y Tanaka, R M Gordon, C Shu, K Fei, S Gao, L Seridi, P Gallagher, K H Lo, P Berry, Q C Zuraw*
- 1564** Pathogenic neuropsychiatric effect of stress-induced microglial interleukin 12/23 axis in systemic lupus erythematosus  
*N Abe, M Tarumi, Y Fujieda, N Takahashi, K Karino, M Uchida, M Kono, Y Tanaka, R Hasebe, M Kato, O Amengual, Y Arinuma, K Oku, W Sato, K K Tha, M Yamasaki, M Watanabe, T Atsumi, M Murakami*
- 1576** Peroxisome proliferator activated receptor- $\gamma$  agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus  
*S Hasni, Y Temesgen-Oyelakin, M Davis, J Chu, E Poncio, M Naqi, S Gupta, X Wang, C Oliveira, D Claybaugh, A Dey, S Lu, P Carlucci, M Purnalek, Z G Manna, Y Shi, I Ochoa-Navas, J Chen, A Mukherjee, K L Han, F Cheung, G Koroleva, Y Belkaid, J S Tsang, R Apps, D E Thomas, T Heller, M Galdina, M P Playford, X Li, N N Mehra, M J Kaplan*

**MORE CONTENTS ►**

This article has been chosen by the Editor to be of special interest or importance and is freely available online.



This article has been made freely available online under the BMJ Journals open access scheme. See <http://authors.bmj.com/open-access/>



Member since 2008  
J.M00004

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

<http://publicationethics.org/>



When you have finished with this please recycle it

## Epidemiology

**1585** SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study

W-J Kim, S-H Choi, J Y Park, J S Song, J-W Chung, S T Choi

**1594** Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study

V Furer, T Eviatar, T Freund, H Peleg, D Paran, D Levartovsky, I Kaufman, A Brojde, O Elalouf, A Polachek, J Feld, A Haddad, T Gazit, M Elkas, N Hgazi, F Kharouf, S Getel, S Pel, S Nevo, D Hagin, D Zisman, O Elkayam

## Behçet's disease

**1603** Behçet's disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity

A Cavers, M C Kugler, Y Ozguler, A F Al-Obeidi, G Hatemi, B M Ueberheide, D Ucar, O Manches, J Nowatzky

## Miscellaneous

**1612** Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016–2017

P Richebé, G Coiffier, P Guggenbuhl, D Mulleman, M Couderc, E Denis, V Deprez, C Salliot, S urien, R Brault, A Ruyssen-Wirand, E Hoppe, E Chatelus, C hubert roux, S Ottaviani, M Baufreere, A Michaut, L Pauvele, C Darrieuort-Laffite, D Wendling, P Coquerelle, G Bart, E Gervais, V Goeb, M Ardizzone, E Pertuiset, S Derolez, J M Ziza, R-M Flipo, S Godot, R Seror

## Images in rheumatology

**1623** Fever, rhinosinusitis and glomerulonephritis with systemic inflammation and antimyeloperoxidase antibody

M Yokota, N Abe, M Bohgaki, H Kasahara

## Electronic pages

**e213** Rational use of tocilizumab in COVID-19

S Jain, S K Sharma

**e214** Targeting IL-6 in COVID-19. Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma

P L Capecchi, P E Lazzerini

**e215** Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma

N Potere, M Di Nisio, D Cibelli, R Scurti, A Frattari, E Porreca, A Abbate, G Parruti

**e216** Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian *et al*

Q Notz, P Meybohm, P Kranke, D Weismann, C Lotz, M Schmalzing

**e217** Response to: 'Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian *et al* by Notz *et al*

A Mathian, Z Amoura

**e218** Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort'

M V Mastrolia, R Agostiniani, C Azzari, R Bernardini, U Bottoni, G B Calabri, F Civitelli, R Consolini, R Danieli, R Di Silvio, S Falorni, L Gagliardi, S Grosso, M Martini, G Memmini, D Peroni, M Pezzati, G Suriano, L Tafi, A Vaccaro, P L Vasari, G Simonini, On behalf of the Paediatric Tuscany Network

**e219** Response to: 'Correspondence on 'Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID19): a multicentre cohort' by Mastrolia *et al*

C Borocco, M Pouletty, C Galeotti, U Meinzer, A Faye, I Koné-Paut, N Ouldali, I Melki

**e220** Correspondence on 'Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences' by Ruscitti *et al*

A I-H Chen, S-C Lin, J C-C Wei

**e221** Response to: 'Correspondence on 'Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences' by Ruscitti *et al*' by Chen *et al*

P Ruscitti, F Bruno, O Berardicurti, C Acampora, V Pavlych, P Palumbo, A Conforti, F Carubbi, I Di Cola, P Di Benedetto, P Cipriani, D Grassi, C Masciocchi, A Iagnocco, A Barile, R Giacomelli

**e222** Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco *et al*. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases

A Giollo, E Bertoldo, G Adami, A J Cybulski, A Fassio, G Orsolini, L Idolazzi, D Gatti, O viapiana, M Rossini

**e223** Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: 'Correspondence on 'Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry' by Gianfrancesco *et al*. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases' by Giollo *et al*

K L Hyrich, M Gianfrancesco, P M Machado, J Yazdany, P C Robinson

- e224** Correspondence to 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'  
*W Zheng, P-Y Leong, J C-C Wei*
- e225** Response to 'Correspondence on 'Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study'' by Zheng *et al*  
*D A Pappas, G St John, C J Etzel, S Fiore, T Blachley, T Kimura, R Punekar, K Emeanuru, J Choi, S Boklage, J M Kremer*
- e226** Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli *et al*  
*J-X Huang, P-Y Leong, J C-C Wei*
- e227** Response to: 'Correspondence on 'Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort' by Micheroli *et al*' by Huang *et al*  
*A Ciurea, R Micheroli*
- e228** Correspondence on 'Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study'  
*Y H Lee*
- e229** Response to: 'Correspondence on 'Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study' by Lee  
*J Xia, L Xu, K-Q Liu, Z-M Ying, S-Y Xie, H-F Zheng*
- e230** Short duration antibiotic therapy for native joint arthritis caused by *Neisseria* infection?  
*M Ducours, S El-Hout, A Desclaux, H Dutronc, T Delhomme, T Fauthoux, F Vercrusse, M Kostine, C Cazanave*
- e231** Response to: 'Short duration antibiotic therapy for native joint arthritis cause by *Neisseria* infection?' by Durcours *et al*  
*I Uçkay, K Vakalopoulos, E Gjika*
- e232** Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'  
*Y Muraviov, L Muraviova*
- e233** Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova  
*P Ruscitti, T A Stamm, R Giacomelli*
- e234** Response to: 'Correspondence on 'Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still's disease'' by Muraviov and Muraviova  
*C Kedor, J Zernicke, E Feist*
- e235** Correspondence on 'Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study'  
*P-C Hung, D-H Lin, A Ker, C-C Yang, H-W Chien, J C-C Wei*
- e236** Response to: 'Correspondence on 'Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study'' by Hung *et al*  
*H B Hammer, L F Karoliussen, L Terslev, E A Haavardsholm, T K Kvien, T Uhlig*
- e237** Severe polymyalgia-like symptoms secondary to anti-PD1 therapy successfully managed without discontinuing checkpoint inhibitor  
*C A Moura, C G Moura*
- e238** Gender gap in rheumatology: speaker representation at annual conferences  
*K Monga, J Liew*